• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Psychiatry

ADHD medication decreases rates of criminality in ADHD patients

bys25qthea
November 30, 2012
in Psychiatry
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: CC/CDC. Prevalence of ADHD (dark = highest)

Dr. Paul Lichtenstein talks to 2 Minute Medicine:Department of Medical Epidemiology and Biostatistics, Karolinska Institute

“One potential implication of this study is that ADHD medication should be seriously considered for adolescents and young adults with ADHD that are at risk for criminality. For instance, research indicates that about 30-40% of long-serving criminals have ADHD. If their risk of recidivism can be reduced by 30%, it would clearly affect total crime numbers in many societies. It should be noted that ADHD medications, like all medications, have potential risks, and the clinician needs to weigh risk and benefits for each patient. Based on our study, we suggest that clinicians also should include the potential decreased risk for criminality in their risk-benefit evaluation.”

 

Key study points:

1. ADHD medication is associated with short term decreases in rates of criminality in men and women in ADHD patients in comparison to periods without medication usage.

RELATED REPORTS

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

Primer: Attention deficit/hyperactivity disorder is present in 3% to 7% of school-age children in the United States, making it the most common neurobehavioral disorder in this group. The disorder commonly presents with over-activity, impulsivity, and/or inattentiveness. ADHD is known to persist into adolescence and adulthood in the majority of patients. While supportive intervention is typically the first line of action for ADHD, there are several pharmacological options that have been used with increasing frequency recently. Among the benefits of ADHD medication, previous studies have demonstrated that typical medications, such as methylphenidate, reduce the incidence of associated conduct problems in children and adults with ADHD. Given such findings, the present study investigated the effect of ADHD medication in reducing criminality overall.

Background reading:

1.  A 30-Year Prospective Follow-up Study of Hyperactive Boys with Conduct Problems

2. Delinquent Behavior and Emerging Substance Use in the MTA at 36 Months: Prevalence, Course, and Treatment Effects

3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review

This [retrospective cohort] study: A total of 16,087 men and 9,569 women with ADHD were investigated via a retrospective pharmacoepidemiologic approach using data from multiple population-based registries in Sweden. Criminality data, defined as any conviction for a crime, was attained through the National Crime Register. Several sensitivity analyses were used to check for and reduce bias in the study.

36.6% of men and 15.4% of women with ADHD were convicted of at least one crime compared to 8.9% and 2.2% of the general population, respectively. Following adjustment for all confounding variables, ADHD medication was shown to reduce criminality by 32% (P<0.001) in men and 41% in women (P<0.001) during treatment periods.

In sum: The findings of this study suggest that ADHD medication reduces the rates of all types of criminality, although this effect does not seem to persist after termination of treatment. One should consider the possibility that patients may stop treatment because of their criminal behavior (reverse causation), but this is unlikely given that the impact of the order of treatment to non-treatment status or vice versa was insignificant. Given the nature of this type of retrospective study, it was unable to account for certain confounders (e.g. alcohol usage or other substance abuse). Also, the study was conducted exclusively in Sweden, and the authors note that there is a large variance in the diagnosis and use of ADHD medications across the world, although Sweden does not appear to be an outlier with respect to cases of ADHD or the use of ADHD medications. Thus, the study provides an additional possible benefit of pharmacological treatment of ADHD, which should be considered by physicians who must weigh the risks and benefits of using pharmacological options for ADHD patients.

Click to read the study in NEJM

By [JP] and [RR]

More from this author: Low dose aspirin shows net clinical benefit in patients with first unprovoked venous thromboembolism, Regular use of aspirin associated with increased survival for mutated-PIK3CA colorectal cancer patients, Poststroke fatigue following nondisabiling stroke associated with impairment of attention and executive function

 

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Previous Post

Patient age & benefit of PCI vs CABG: PCI better outcomes for younger patients, CABG better outcomes for older patients

Next Post

Pediatric patients not receiving quality palliative care despite agreement between parents and caregivers on valued elements of care

RelatedReports

Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.
2MM Trial Briefs

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

October 25, 2026
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

October 25, 2026
An older woman looks thoughtfully to the side, with dumbbells, running shoes, and a bottle of supplements nearby, suggesting themes of exercise and health in geriatrics.
Chronic Disease

An electronic health record tool for exercise prescription may reduce fall rate among older adults

October 24, 2026
A woman using a red light therapy device while seated, surrounded by workout equipment and papers, suggesting engagement in wellness practices.
Chronic Disease

Optogenetic therapy may partially restore vision in retinitis pigmentosa

October 23, 2026
Next Post

Pediatric patients not receiving quality palliative care despite agreement between parents and caregivers on valued elements of care

Patients who utilize online health services make greater use of in-person services

Mosaic osteochondral autologous transplantation shows benefits over microfracture for the treatment of osteochondral defects in the knee joint of athletes

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results
  • Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial
  • An electronic health record tool for exercise prescription may reduce fall rate among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.